Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2009-5-29
pubmed:abstractText
Survival of metastatic gastroenteropancreatic well-differentiated endocrine carcinoma (GEP WDEC) is not well characterized. We evaluated the long-term outcome and prognostic factors for survival in 118 patients with distant metastases from GEP WDEC. Inclusion criteria were 1) pathological review by a single pathologist according to the present WHO criteria, 2) absence of previous therapy apart from surgery, 3) complete morphological evaluation within 3 months including somatostatin receptor scintigraphy, and 4) follow-up at Gustave-Roussy Institute until death or study's end. Clinical, biological marker, and pathological parameters were analyzed in univariate and multivariate statistical models. Survival after the first complete imaging work-up of the metastatic disease was determined using Kaplan-Meier method. Overall, survival for 5 years after the diagnosis of metastatic disease was 54%. In multivariate analysis, age (hazard ratio (HR): 1.05, 95% confidence interval (CI): 1.01-1.08, P = 0.01), the number of liver metastases (HR: 3.4, 95% CI: 1.4-8.3, P = 0.01), tumor slope (HR: 1.1, 95% CI: 1.0-1.1, P = 0.001), and initial surgery (HR: 0.3, 95% CI: 0.1-0.8, P = 0.01) were predictive of survival. Five-year survival was 100%, 91% (95% CI, 51-98%), 62% (95% CI, 37-83%), and 9% (95% CI, 6-32%) when patients had 0, 1, 2, 3 or more poor prognostic features respectively. This study enables the stratification of metastatic GEP WDEC patients into distinct risk groups. These risk categories can be used to tailor therapeutic approaches and also to design and interpret clinical trials.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1351-0088
pubmed:author
pubmed:issnType
Print
pubmed:volume
16
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
585-97
pubmed:meshHeading
pubmed-meshheading:19240182-Adolescent, pubmed-meshheading:19240182-Adult, pubmed-meshheading:19240182-Aged, pubmed-meshheading:19240182-Aged, 80 and over, pubmed-meshheading:19240182-Cell Differentiation, pubmed-meshheading:19240182-Child, pubmed-meshheading:19240182-Female, pubmed-meshheading:19240182-Gastrointestinal Neoplasms, pubmed-meshheading:19240182-Humans, pubmed-meshheading:19240182-Male, pubmed-meshheading:19240182-Middle Aged, pubmed-meshheading:19240182-Neoplasm Staging, pubmed-meshheading:19240182-Neuroendocrine Tumors, pubmed-meshheading:19240182-Pancreatic Neoplasms, pubmed-meshheading:19240182-Prognosis, pubmed-meshheading:19240182-Retrospective Studies, pubmed-meshheading:19240182-Risk Factors, pubmed-meshheading:19240182-Survival Rate, pubmed-meshheading:19240182-Young Adult
pubmed:year
2009
pubmed:articleTitle
Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma.
pubmed:affiliation
Service de Médecine Nucléaire et de Cancérologie Endocrinienne, Institut Gustave-Roussy, Université Paris XI, 94805 Villejuif Cedex, France.
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, N.I.H., Extramural, Research Support, N.I.H., Intramural